CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice

April 13, 2018
ANCERS-2
Breast Cancer, Colorectal Cancer, Head and Neck, Ovarian Cancer
George I Salti, MD
Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

The purpose of this study is to test the CANscript™ sensitivity assay, which is a new and different assay developed to test the sensitivity of different cancer types to physician selected therapies (both drugs and/or drug combinations) indicated for the stage and type of cancer for treatment. CANscript™ tests how a patients specific tumor reacts to the therapies being considered by the treating physician. CANscript™ test results have been shown to closely correspond with actual clinical results, providing physicians with information that may help him/her develop a more personalized cancer treatment and care plan based on the patients specific condition. The researchers want to see if CANscript™ test results are helpful in selecting the treatments prescribed and provided. There will be about 800 people taking part in this study, across 5 different tumor types. The study is designed to assess the decision impact of the CANscript™ test results in informing physicians in therapy selection.

Sponsor: Mitra RxDx, Inc.

https://clinicaltrials.gov/ct2/show/NCT03253575

  • ECOG performance status of ≤ 2
  • tumor must be amenable to a tumor biopsy sampling
  • disease measurable by standard imaging techniques
  • no additional active malignancy that may confound the assessment of the study endpoints
  • no clinically significant cardiovascular or pulmonary disease
  • no known active or suspected brain or leptomeningeal metastases
  • not pregnant or breast-feeding
2 years
Accepting Participants
Observational
Kathy Seymour, BSN
630-646-6075
630-646-6110
630-646-6072